RN7SL319P

Across TCGA pan-cancer cohorts, RN7SL319P Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RN7SL319P data layer compared with 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RN7SL319P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RN7SL319P expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

STAD, UCEC, and LUAD are the cancer types where RN7SL319P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.196	0.676	.008	30	view →
UCEC	DFS	Median	All	1.000	0.629	.023	12	view →
LUAD	DFS	Median	II,III,IV	1.000	0.233	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RN7SL319P–STAD (OS)

Open the STAD breakdown →